On March 31, 2026, OS Therapies Incorporated filed a Form 8-K with the U.S. Securities and Exchange Commission (SEC) to report the filing of a prospectus supplement. This supplement is part of the company's registration statement on Form S-3, which was initially filed on August 8, 2025, and declared effective on August 12, 2025. The prospectus supplement covers the resale of up to 10,529,417 shares of the company's common stock by certain selling stockholders. The filing aims to provide a legal opinion from Olshan Frome Wolosky LLP regarding the legality of these shares, which is included as Exhibit 5.1 in the filing. This move is expected to enhance liquidity for the company's stock, allowing existing shareholders to sell their shares in the market. The company is incorporated in Delaware and trades under the symbol OSTX on the NYSE American exchange. The filing indicates that OS Therapies is an emerging growth company, which may influence its reporting and compliance obligations moving forward.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.